Clinical Trial Update: A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating clifutinib in patients with relapsed or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Clifutinib (clifutinib)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED